Evidence map›Paper›PMID 26205579›Full record

ArticleExperimental dermatology2015

Unique microRNAs appear at different times during the course of a delayed-type hypersensitivity reaction in human skin.

Nicholas Gulati, Marianne B Løvendorf, John R Zibert, Kemal M Akat, Neil Renwick, Thomas Tuschl, James G Krueger

Open access · greenAbstract read
In one paragraph

Article in Experimental dermatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. MiR-200c-3p as a novel genetic marker and therapeutic tool for alopecia areata.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024
    Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Nicholas GulatiLaboratory for Investigative Dermatology, The Rockefeller University, New York, NY, USA.
Marianne B LøvendorfLEO Pharma A/S, Ballerup, Denmark.
John R ZibertLEO Pharma A/S, Ballerup, Denmark.
Kemal M AkatHHMI Laboratory of RNA Molecular Biology, Howard Hughes Medical Institute, The Rockefeller University, New York, NY, USA.
Neil RenwickHHMI Laboratory of RNA Molecular Biology, Howard Hughes Medical Institute, The Rockefeller University, New York, NY, USA.
Thomas TuschlHHMI Laboratory of RNA Molecular Biology, Howard Hughes Medical Institute, The Rockefeller University, New York, NY, USA.
James G KruegerLaboratory for Investigative Dermatology, The Rockefeller University, New York, NY, USA.
Rockefeller University · USLeo Pharma (Denmark) · DKUniversity of Copenhagen · DK

Funding

Weill Cornell/Rockefeller/Sloan-Kettering MST ProgramT32GM007739 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI HSU, KATHARINE C · 1985 to 2023
$51.1M
TRANSFORMING TRANSLATIONAL SCIENCE AND EDUCATION TO BENEFIT HUMAN HEALTHUL1RR024143 · NCRR · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY · 2006 to 2011
$49.1M
Howard Hughes Medical InstituteNCRR NIH HHS UL1 RR024143NIGMS NIH HHS T32 GM007739NIGMS NIH HHS T32GM07739
6 · The paper itself

Abstract

Diphencyprone (DPCP) is a hapten that induces delayed-type hypersensitivity (DTH) reactions. MicroRNAs (miRNAs) are short non-coding RNAs that negatively regulate gene expression and have been implicated in various inflammatory skin diseases, but their role in DTH reactions is not well understood. We generated global miRNA expression profiles (using next-generation sequencing) of DPCP reactions in skin of seven healthy volunteers at 3, 14 and 120 days after challenge. Compared to placebo-treated sites, DPCP-challenged skin at 3 days (peak inflammation) had 127 miRNAs significantly deregulated. At 14 days (during resolution of inflammation), 43 miRNAs were deregulated and, at 120 days (when inflammation had completely resolved), six miRNAs were upregulated. While some miRNAs have been observed in psoriasis or atopic dermatitis, most of the deregulated miRNAs have not yet been studied in the context of skin biology or immunology. Across the three time points studied, many but not all miRNAs were uniquely expressed. As various miRNAs may influence T cell activation, this may indicate that the miRNAs exclusively expressed at different time points function to promote or resolve skin inflammation, and therefore, may inform on the paradoxical ability of DPCP to treat both autoimmune conditions (alopecia areata) and conditions of ineffective immunity (melanoma).

Indexed as

AdultCyclopropanesFemaleHaptensHumansHypersensitivity, DelayedMaleMicroRNAsMiddle AgedSkinTime FactorsTranscriptomeYoung AdultCyclopropanesdiphenylcyclopropenoneHaptensMicroRNAsMIRN21 microRNA, humanMIRN383 microRNA, humanMIRN503 microRNA, humanMIRN7-1 microRNA, humandelayed-type hypersensitivitydiphencypronemicroRNAnext-generation sequencing

Identifiers

PMID26205579
PMCPMC4701645
OpenAlexW1492802368

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.